Chief Executive Officer Koblish Antony was granted 149,000 shares and covered exercise/tax liability with 17,403 shares, increasing direct ownership by 29% to 590,494 units (SEC Form 4)

$TELA
Medical/Dental Instruments
Health Care
Get the next $TELA alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KOBLISH ANTONY

(Last) (First) (Middle)
C/O TELA BIO, INC.
1 GREAT VALLEY PARKWAY, SUITE 24

(Street)
MALVERN PA 19355

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
TELA Bio, Inc. [ TELA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/21/2025 A 149,000(1) A $0 607,897 D
Common Stock 02/23/2025 F 11,631(2) D $2.72 596,266 D
Common Stock 02/24/2025 F 5,772(2) D $2.65 590,494 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $2.72 02/21/2025 A 219,000 (3) 02/21/2035 Common Stock 219,000 $0 219,000 D
Explanation of Responses:
1. These restricted stock units ("RSUs") will vest in four equal annual installments beginning on February 21, 2026, subject to the Reporting Person's continuous service through the applicable vesting dates.
2. Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs.
3. The option vests 25% on February 21, 2026, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.
/s/ Megan Smeykal, Attorney-in-fact 02/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $TELA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TELA

DatePrice TargetRatingAnalyst
3/21/2025$5.00 → $2.00Overweight → Neutral
Piper Sandler
5/31/2022$17.00Buy
Lake Street
More analyst ratings

$TELA
Press Releases

Fastest customizable press release news feed in the world

See more
  • TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results

    MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the full year 2024, resulting in growth in unit sales volume for each product of approximately 33% and 31%, r

    $TELA
    Medical/Dental Instruments
    Health Care
  • TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results

    MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 20, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Fourth Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15

    $TELA
    Medical/Dental Instruments
    Health Care
  • TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 7,200 shares of its common stock to thirteen newly-hired employees, with a grant date of February 19, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his

    $TELA
    Medical/Dental Instruments
    Health Care

$TELA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TELA
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$TELA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TELA
SEC Filings

See more

$TELA
Leadership Updates

Live Leadership Updates

See more
  • TELA Bio Appoints Jeffrey Blizard to its Board of Directors

    MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024. "We are excited to have Jeff join our Board as we continue to develop and optimize our sales force," said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio. "Jeff's exceptional sales leader

    $TELA
    Medical/Dental Instruments
    Health Care
  • TELA Bio Appoints Greg Firestone as Chief Commercial Officer

    MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company's new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company's commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across the Company's product lines. "Greg has been an instrumental player in the TELA Bio story, supporting our commercial strategy and cultivating each of our key group

    $TELA
    Medical/Dental Instruments
    Health Care
  • TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

    MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy. Dr. Langstein is the former Chief of Plastic and Reconstructive Surgery at the University of Rochester Medical Center, known for his extensive expertise, especially in microvascular reconstruction and innovative approaches to complex surgical problems. Dr. Langstein previously held the position of Associate Professor of Plastic Surgery at the University of Texas MD Anderson Cancer Center, where

    $TELA
    Medical/Dental Instruments
    Health Care

$TELA
Financials

Live finance-specific insights

See more
  • TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results

    MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the full year 2024, resulting in growth in unit sales volume for each product of approximately 33% and 31%, r

    $TELA
    Medical/Dental Instruments
    Health Care
  • TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results

    MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 20, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Fourth Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15

    $TELA
    Medical/Dental Instruments
    Health Care
  • TELA Bio to Announce Third Quarter 2024 Financial Results

    MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2024 financial results on Thursday, November 7, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Third Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before

    $TELA
    Medical/Dental Instruments
    Health Care

$TELA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more